Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Pathology and Oncology Research - Netherlands
doi 10.1007/s12253-020-00809-z
Full Text
Open PDFAbstract
Available in full text
Date
April 15, 2020
Authors
Publisher
Springer Science and Business Media LLC